Medication safety in brief
The labeling for dextroamphetamine (Dexedrine, GlaxoSmithKline) was revised to include new warnings. The warnings describe reports of sudden death in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.
The labeling for dextroamphetamine (Dexedrine, GlaxoSmithKline) was revised to include new warnings. The warnings describe reports of sudden death in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.
Recently reported Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) Program results demonstrated that the rate of confirmed thrombotic cardiovascular (CV) events was similar between etoricoxib (Arcoxia, Merck) and diclofenac. Specifically, in the pre-specified "per-protocol" analysis of the primary end point, the relative risk of confirmed thrombotic CV events between etoricoxib and diclofenac was 0.95 (95% CI, 0.81–1.11).
In the MEDAL study, the incidence of discontinuations due to hypertension-related adverse events was significantly higher for etoricoxib compared with diclofenac. Also in the MEDAL study, the incidence of discontinuations due to edema-related adverse events was significantly higher only for etoricoxib 90 mg compared with diclofenac, and the incidence of adjudicated and confirmed cases of congestive heart failure trended higher only for etoricoxib 90 mg compared with diclofenac.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
